[
  {
    "ts": null,
    "headline": "Medtronic (MDT)’s CEO “is One of the Finest People,” Says Jim Cramer",
    "summary": "We recently published 13 Stocks That Crossed Jim Cramer’s Radar. Medtronic plc (NYSE:MDT) is one of the stocks Jim Cramer discussed. Medtronic plc (NYSE:MDT) is a medical technology company that makes and sells devices for cardiovascular, neuroscience, and surgical applications. Cramer has discussed the firm on a handful of occasions in 2025. One such discussion […]",
    "url": "https://finnhub.io/api/news?id=73a6028aa192f49f65eebd823f0adb1d726633339a6f574c76b94c2d72b24ca8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763752889,
      "headline": "Medtronic (MDT)’s CEO “is One of the Finest People,” Says Jim Cramer",
      "id": 137572195,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently published 13 Stocks That Crossed Jim Cramer’s Radar. Medtronic plc (NYSE:MDT) is one of the stocks Jim Cramer discussed. Medtronic plc (NYSE:MDT) is a medical technology company that makes and sells devices for cardiovascular, neuroscience, and surgical applications. Cramer has discussed the firm on a handful of occasions in 2025. One such discussion […]",
      "url": "https://finnhub.io/api/news?id=73a6028aa192f49f65eebd823f0adb1d726633339a6f574c76b94c2d72b24ca8"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Today: Dow Rebounds In Wild Action; AMD Sees More Selling As Nvidia Climbs (Live Coverage)",
    "summary": "The Dow Jones Industrial Average rebounded sharply in a day of seesaw action across the major indexes Friday, and looked to end the week on a high note. The Dow rallied 1.5%, or around 670 points Friday afternoon, and bolted past the 46,000 level, after closing below it Thursday.",
    "url": "https://finnhub.io/api/news?id=b9930b818a05f4c2b36cc378bde520d20651e935ec214c4b49e459fcc3dff914",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763752867,
      "headline": "Stock Market Today: Dow Rebounds In Wild Action; AMD Sees More Selling As Nvidia Climbs (Live Coverage)",
      "id": 137571826,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The Dow Jones Industrial Average rebounded sharply in a day of seesaw action across the major indexes Friday, and looked to end the week on a high note. The Dow rallied 1.5%, or around 670 points Friday afternoon, and bolted past the 46,000 level, after closing below it Thursday.",
      "url": "https://finnhub.io/api/news?id=b9930b818a05f4c2b36cc378bde520d20651e935ec214c4b49e459fcc3dff914"
    }
  },
  {
    "ts": null,
    "headline": "AZN Wins FDA Nod for Expanded Use of Rare Disease Drug, Koselugo",
    "summary": "AstraZeneca secures FDA approval to expand Koselugo's use to treat adult NF1 patients with inoperable PN.",
    "url": "https://finnhub.io/api/news?id=294d216f7ef22a98941ae7ce0def815b82643274b8709f5e0fa5e8a660b6a6eb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763738100,
      "headline": "AZN Wins FDA Nod for Expanded Use of Rare Disease Drug, Koselugo",
      "id": 137572197,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "AstraZeneca secures FDA approval to expand Koselugo's use to treat adult NF1 patients with inoperable PN.",
      "url": "https://finnhub.io/api/news?id=294d216f7ef22a98941ae7ce0def815b82643274b8709f5e0fa5e8a660b6a6eb"
    }
  },
  {
    "ts": null,
    "headline": "PFE's New & Acquired Drugs Drive Non-COVID Comeback as LOE Test Looms",
    "summary": "Pfizer's new and acquired drugs lift non-COVID revenue, with recent launches and Seagen products driving momentum into 2026 despite looming LOEs.",
    "url": "https://finnhub.io/api/news?id=057630b543edc31b29ebefc8c520e7b265def2a2f0c556ac5203d3261213b47f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763728860,
      "headline": "PFE's New & Acquired Drugs Drive Non-COVID Comeback as LOE Test Looms",
      "id": 137572198,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Pfizer's new and acquired drugs lift non-COVID revenue, with recent launches and Seagen products driving momentum into 2026 despite looming LOEs.",
      "url": "https://finnhub.io/api/news?id=057630b543edc31b29ebefc8c520e7b265def2a2f0c556ac5203d3261213b47f"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Visa, Merck, Southern Company, Community Bancorp and Comstock",
    "summary": "V benefits from rising cross-border volumes and strong digital payments momentum as analysts spotlight broad performance drivers across key sectors.",
    "url": "https://finnhub.io/api/news?id=ba33bb420ab7b87809344eb3e90d078428b3b9bb95503579872898efae376f7f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763720220,
      "headline": "The Zacks Analyst Blog Highlights Visa, Merck, Southern Company, Community Bancorp and Comstock",
      "id": 137572199,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "V benefits from rising cross-border volumes and strong digital payments momentum as analysts spotlight broad performance drivers across key sectors.",
      "url": "https://finnhub.io/api/news?id=ba33bb420ab7b87809344eb3e90d078428b3b9bb95503579872898efae376f7f"
    }
  },
  {
    "ts": null,
    "headline": "GSK, Anaptysbio sue each other over Jemperli revenue",
    "summary": "As Anaptysbio seeks to split off a royalty business, both companies claim the other breached contracts surrounding development of the cancer immunotherapy.",
    "url": "https://finnhub.io/api/news?id=03ca1187735a08b8f93aefa3abe9906cbaaa9b5980c881be3d8c91795f152ad5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763716413,
      "headline": "GSK, Anaptysbio sue each other over Jemperli revenue",
      "id": 137572200,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "As Anaptysbio seeks to split off a royalty business, both companies claim the other breached contracts surrounding development of the cancer immunotherapy.",
      "url": "https://finnhub.io/api/news?id=03ca1187735a08b8f93aefa3abe9906cbaaa9b5980c881be3d8c91795f152ad5"
    }
  },
  {
    "ts": null,
    "headline": "Retirement: 2 Healthcare Giants To Buy At Discounted Prices",
    "summary": "Merck and Elevance Health stocks are top dividend growth picks with solid yields and attractive valuations. Click here to learn more about MRK and ELV.",
    "url": "https://finnhub.io/api/news?id=fb9424a0da59a9e5653f3e72f4a6ad136fe11ef58280ca7e6dff2062036ae04e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763712000,
      "headline": "Retirement: 2 Healthcare Giants To Buy At Discounted Prices",
      "id": 137568760,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2181565926/image_2181565926.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Merck and Elevance Health stocks are top dividend growth picks with solid yields and attractive valuations. Click here to learn more about MRK and ELV.",
      "url": "https://finnhub.io/api/news?id=fb9424a0da59a9e5653f3e72f4a6ad136fe11ef58280ca7e6dff2062036ae04e"
    }
  }
]